University of Amsterdam

Wednesday February 12, 2025 – Scenic Biotech announced the appointment of Alexander Vos as Chairman to its Board of Directors. With more than 30 years of CEO and Board member experience across the biotech industry, Alexander brings a track record of growing and advancing biopharmaceutical companies, with a focus on rare and orphan diseases and cell and gene therapies. Scenic Biotech would also like to thank our previous Chairman, Philippe Dro, for his years of service and contributions. “I’m joining Scenic Biotech’s Board of Directors as the company makes great strides in advancing their lead modifier program through preclinical studies. Scenic’s approach holds significant potential in a range of neuro- and metabolic diseases and I look forward to supporting the team in bringing this approach to patients,” said Alexander Vos, Chairman of Scenic’s Board of Directors. Alexander began his career at McKinsey & Co. in 1989 after which he joined Genzyme Europe in 1994. At Genzyme, he held several executive roles, including leading a global joint venture with Pharming NV to develop and commercialize the enzyme human alpha-glucosidase as a treatment for Pompe’s disease. Thereafter he led a number of public and private biotech companies across Europe, including two towards successful investor exits. He currently serves on the boards of several biotech companies in the USA, the United Kingdom and continental Europe. Alexander holds an MS in Pharmacy and Pharmacology from the University of Amsterdam and an MBA from Stanford University. About Scenic Biotech Scenic Biotech is advancing modifier therapy, a radically new approach to treating genetic disorders. Instead of targeting the primary disease-causing mutation, modifier therapy seeks to rebalance health by acting on another function in the genome that can neutralize the disease impact, leading to a therapeutic effect. Our robust pipeline, derived from our proprietary Cell-seq platform, includes first-in-class small molecule programs that are either wholly owned or partnered through strategic collaborations with multinational pharmaceutical leaders. By unlocking new pathways in the genome, Scenic will develop a range of modifier therapies to help patients. For more information, please contact: Scenic Biotech Oscar Izeboud, PhD, CEO Phone: +31 20 705 9990 Email: oscar.izeboud@scenicbiotech.com Trophic Communications Eva Mulder / Desmond James Phone: +31 6 52 33 15 79 or +49 151 6785 9086 Email: scenic@trophic.eu

Former senior vice president of antibody research at Genmab who has co-invented numerous FDA-approved therapeutic antibodies and as well as its DuoBody® bi-specific antibody platform Brings decades of experience in developing strong pipelines of antibody-based drugs from platforms, growing scientific teams and managing partnerships with Pharma companies Appointment comes as Commit looks to progress towards drug candidate (DC) nomination in cancer and autoimmune disease in 2025 AARHUS, Denmark, Jan. 8, 2025 /PRNewswire/ -- Commit Biologics ("Commit"), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today announces the appointment of Janine Schuurman, Ph.D. to its Board of Directors. Dr Schuurman is a widely recognized scientific leader with over 25 years' experience in antibody research, discovery, and development. She is the co-inventor of several FDA approved drugs, including amivantamab (RYBREVANT® Janssen) and epcoritamab (EPKINLY® Genmab/Abbvie). Dr Schuurman also played a key role in the development of antibody platform technologies while at Genmab, such as DuoBody® and HexaBody®, and rose to become Senior Vice President, Head of Antibody Research and Development. A renowned speaker at scientific conferences, Dr Schuurman is currently President of The Antibody Society, a highly regarded non-profit supporting antibody-related research and development. Krishna Polu, MD, Chief Executive Officer of Commit Biologics, said: "Janine brings a wealth of knowledge and experience that will greatly benefit Commit - both in terms of the science of antibody research and development, and in the practical know-how of building teams, pipelines and partnerships that is so essential to achieving drug approvals success. Her experience in developing meaningful therapeutic antibodies and antibody platforms will be invaluable. We look forward to partnering with her and the board to advance Commit's BiCE platform to DC candidate selection in 2025." Janine Schuurman, PhD, newly appointed Board Member of Commit Biologics, said: "Commit's BiCE platform, which has the potential to give antibody therapeutics the power to strongly activate the complement system, is an extremely exciting technology. I look forward to helping Commit advance BiCE from platform to pipeline, using all the scientific and operational experience I have gained over the years I have been successfully developing antibody-based drugs." Dr Schuurman holds a PhD in molecular immunology from the University of Amsterdam. Commit Biologics is advancing development of its Bispecific Complement Engaging (BiCE™) technology, which is designed to potently activate the complement system – a part of the immune system which has often been overlooked in terms of its therapeutic potential. BiCE uses single domain antibodies that bind to the complement protein C1q, thus directing the complement system in a highly selective way against tumor cells or cells implicated in autoimmune disease. Dr Schuurman, who previously served as a scientific advisor to Commit, joins its Board of Directors with immediate effect. About Commit Biologics Commit Biologics (Commit) is a pioneer in activating the complement system to kill specific target cells, with applications in cancers and autoimmune diseases. Spun out of Aarhus University, and building on more than three decades of research, Commit's Bispecific Complement Engaging (BiCE™) platform can supercharge a conventional monoclonal antibody to activate the complement system more effectively. This is achieved by combining single domain antibodies that engage C1q, the starting point for the complement activation cascade, with an antibody that binds to a cellular target. The modular approach of the BiCE™ technology can be used to develop therapeutics across multiple tumor-associated antigens and immune cell targets. Complement is a largely untapped aspect of the body's natural immune system that leverages both the direct cytolytic activity of complement along with its ability to bridge recruitment and activation of both innate and adaptive immune cells – a new approach to killing cells which can be used in combination or on a standalone basis. Commit is backed by major investors including Bioqube Ventures, Novo Holdings and Korys. About the complement system The complement system is part of the body's immune system that has previously been largely untapped therapeutically. The activation of the classical complement pathway, which has a role in health for pathogen defense, begins with the engagement of C1q to antibodies that coat the cell surface and ends with the activation of a cytolytic complement complex directly leading to cell lysis. However, current monoclonal antibodies developed for therapeutic purposes have structural restraints that hinder effective engagement to C1q, thus limiting complement mediated cytotoxicity and other complement mediated effector functions. This, plus the presence of natural cell bound complement inhibitors that are upregulated in cancer, and low target densities, make conventional therapeutic antibodies poor complement activators. Commit's BiCE™ technology was developed to overcome these barriers, to harness the power of the complement system and direct it towards tumor and immune cells for therapeutic applications. Unleashing this power in a highly targeted way with Commit's technology potentially allows for a broad therapeutic index and the development of highly effective treatments. SOURCE Commit Biologics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

PORTO, Portugal--( BUSINESS WIRE )--FairJourney Biologics S.A., leaders in the discovery and optimization of antibodies, today announced it has established a Scientific Advisory Board (SAB) to support its strategy for ongoing growth and innovation. The advisory board comprises renowned industry experts appointed to support the identification of strategic opportunities, enhance scientific excellence, and drive the development of cutting-edge technologies. This alignment ensures the Company remains at the forefront of antibody discovery, addressing market needs and future trends. António Parada, CEO of FairJourney Biologics, commented: “The addition of the Scientific Advisory Board to our team marks a significant milestone for FairJourney Biologics. Their collective expertise will guide our scientific efforts, helping us accelerate growth and deliver the next generation of antibody discovery technologies to our customers and stakeholders.” Dr. Janine Schuurman joins as Chair of FairJourney Biologics’ SAB. Her career has centered around innovative research and new technology in antibody discovery and development for novel therapeutic modalities. She was Senior Vice President, Head Antibody Research & Technology at Genmab, joining in 2000 as one of the first ten employees on the R&D team and going on to hold several senior positions over 22 years at the Company. Janine has co-invented an impressive portfolio of therapeutic antibodies, approved and in clinical and pre-clinical development, and antibody discovery and development platforms. She advises a number of companies and collaborates with leading industry organizations, including as President of The Antibody Society. Janine holds a Ph.D. in Molecular Immunology from the University of Amsterdam. Janine commented: " FairJourney Biologics is established as a global leader in antibody discovery services. As SAB Chair, I am very much looking forward to joining the Company’s journey to broaden innovation and its impact on the industry .” Dr. Elaine Sullivan brings over 25 years of industry experience; holding senior executive positions at several pharma and biotech companies, including as a member of the Senior Global R&D management team at Eli Lilly and Company and AstraZeneca. Elaine was Vice President R&D; Head of New Opportunities Therapy Area at AstraZeneca, and having been at the Company for over 16 years, moved to Eli Lilly as Vice President of Global External Research & Development. She co-founded and led Carrick Therapeutics as CEO, has established 14 new companies, and gained extensive international Non-executive Director Board expertise in public companies across Europe. Elaine gained her Ph.D. in Molecular Virology from The University of Edinburgh. Dr. Tariq Ghayur has over 30 years’ experience leading multi-disciplinary, cross-therapeutic area Biologics discovery programs and developing novel biologics platforms in different organizations, including BASF Pharma, Abbott Laboratories, and most recently as Distinguished Research Fellow and Head of Foundational Immunology Department at AbbVie. Several of the Biologics programs Tariq’s teams pioneered have resulted in clinical development candidates. He holds a Ph.D. in Immunology from McGill University and completed his post-doctoral training at Dana Farber Cancer Institute. Dr. Victor Greiff is an Associate Professor for Systems Immunology at the University of Oslo and the Director of Computational Immunology at Imprint Labs, a non-profit focused research organization for immunology. His group develops machine learning, computational and experimental tools for immune-repertoire-based in silico immunodiagnostics and immunotherapeutics discovery and design. Victor received his Ph.D. in Systems Immunology from Humboldt University and performed his postdoctoral training at ETH Zürich. For more information, please visit: https://fjbio.com/